Table 1 Characteristics of study participants
PD (n = 38) | HD (n = 76) | CKD (n = 38) | p value | |
|---|---|---|---|---|
Age (years) | 62.74 ± 14.45 | 61.93 ± 12.43 | 62.81 ± 10.59 | 0.918 |
Female (n, %) | 15 (39.5%) | 30 (39.5%) | 15 (39.5%) | 1.000 |
Dialysis vintage (months) | 18.53 (10.94–35.59) | 24.47 (11.83–40.88) | 0.714 | |
CKD stage (for CKD group) | ||||
Stage 2 | 7 (18.4%) | |||
Stage 3 | 19 (50%) | |||
Stage 4 | 12 (31.6%) | |||
Type of PD (n, %) (for PD group) | ||||
CAPD | 12 (31.6%) | |||
APD | 26 (68.4%) | |||
BMI (kg/m2) | 28.52 ± 5.68 | 26.7 ± 4.95 | 30.15 ± 7.45 | 0.012 |
Urine volume (ml) | 800 (100–1312.5) | 175 (0–575) | 2200 (1700–2500) | <0.001 |
Diabetes mellitus (n, %) | 9 (23.7)% | 31 (40.8%) | 15 (39.5%) | 0.178 |
Hypertension (n, %) | 33 (86.8%) | 57 (75%) | 38 (100%) | 0.002 |
Dyslipidemia (n, %) | 22 (57.9%) | 33 (44.6%) | 22 (57.9%) | 0.265 |
Cardiovascular disease (n, %) | 17 (44.7%) | 35 (46.1%) | 13 (34.2%) | 0.465 |
Coronary heart disease (n, %) | 8 (21.1%) | 30 (39.5%) | 5 (13.5%) | 0.008 |
Heart failure (n, %) | 9 (23.7%) | 13 (17.1%) | 2 (5.3%) | 0.080 |
Peripheral vascular disease (n, %) | 5 (13.15%) | 9 (11.8%) | 5 (13.2%) | 1.000 |
Stroke (n, %) | 2 (5.3%) | 5 (6.6%) | 3 (7.9%) | 1.00 |
Atrial fibrilation (n, %) | 4 (10.5%) | 2 (2.6%) | 4 (10.5%) | 0.61 |
Smoking (n, %) | 7 (18.4%) | 14 (19.7%) | 9 (23.7%) | 0.833 |
Total antihypertensive drugs (n) | 2.32 ± 1.34 | 1.72 ± 1.3 | 2.66 ± 1.38 | 0.001 |
ACEis/ARBs (n, %) | 20 (52.6%) | 15 (19.7%) | 25 (65.8%) | <0.001 |
CCBs (n, %) | 15 (39.5%) | 24 (31.6%) | 24 (63.2%) | 0.005 |
B blockers (n, %) | 27 (71.1%) | 47 (61.8%) | 19 (50%) | 0.168 |
Diuretics (n, %) | 22 (57.9%) | 18 (23.7%) | 19 (50%) | 0.001 |
Other antihypertensives (n, %) | 7 (18.4%) | 15 (19.7%) | 9 (23.7%) | 0.903 |
